Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

ClinicalTrials.gov ID: NCT01436162

Public ClinicalTrials.gov record NCT01436162. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions: * How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? * Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant? * How much SPD489 should be given to patients with depression who are also taking an antidepressant? * How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?

Study identification

NCT ID
NCT01436162
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Shire
Industry
Enrollment
1,105 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 18, 2011
Primary completion
Dec 9, 2013
Completion
Dec 9, 2013
Last update posted
Jun 8, 2021

2011 – 2013

United States locations

U.S. sites
36
U.S. states
18
U.S. cities
34
Facility City State ZIP Site status
ResearchOne, Inc. Scottsdale Arizona 85251
K&S Professional Research Services, LLC Little Rock Arkansas 72201
ATP Clinical Research, Inc. Costa Mesa California 92626
Diligent Clinical Trials Downey California 90241
Synergy Clinical Reserach Center of Escondido Escondido California 92025
Pacific Research Partners, LLC Oakland California 94612
Anderson Clinical Research Redlands California 92374
BreakThrough Clinical Trials, LLC San Bernardino California 92408
MCB Clinical Research Centers Colorado Springs Colorado 80910
Florida Clinical Research Center, LLC Bradenton Florida 34201
Scientific Clinical Research, Inc. North Miami Florida 33161
Clinical Neuroscience Solutions, Inc. Orlando Florida 32806
Comprehensive NeuroScience, Inc. St. Petersburg Florida 33716
Janus Center for Psychiatric Research West Palm Beach Florida 33407
Atlanta Center for Medical Research Atlanta Georgia 30308
Atlanta Institute of Medicine & Research Atlanta Georgia 30328
Pedia Research Newburgh Indiana 47630
Heartland Research Associates Wichita Kansas 67207
Louisiana Clinical Research, LLC Shreveport Louisiana 71115
Comprehensive Psychiatric Associates Gladstone Missouri 64118
The Center for Pharmaceutical Research Kansas City Missouri 64114
Mercy Health Research St Louis Missouri 63141
Bio Behavioral Health Toms River New Jersey 08755
Brooklyn Medical Institute Brooklyn New York 11214
Medical & Behavioral Health Research, PC New York New York 10023
Midwest Clinical Research Center Dayton Ohio 45417
North Star Medical Research, LLC Middleburg Heights Ohio 44130
Sooner Clinical Research Oklahoma City Oklahoma 73112
Lehigh Center for Clinical Research Allentown Pennsylvania 18104
Belmont Center for Comprehensive Treatment Philadelphia Pennsylvania 19131
Medical University South Carolina Anxiety Disorder Program North Charleston South Carolina 29406
Psychiatric Consultants, PC Franklin Tennessee 37067
Research Strategies of Memphis, LLC Memphis Tennessee 38119
KRK Medical Research Dallas Texas 75230
Future Search Trials of Dallas, LP Dallas Texas 75231
Clinical Trials of Texas, Inc. San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01436162, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 8, 2021 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01436162 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →